Search Orphan Drug Designations and Approvals
-
| Generic Name: | plerixafor | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Mozobil (r) | ||||||||||||||||
| Date Designated: | 07/10/2003 | ||||||||||||||||
| Orphan Designation: | For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Genzyme Corporation 500 Kendall Street Cambridge, Massachusetts 02142 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | plerixafor |
|---|---|---|
| Trade Name: | Mozobil (r) | |
| Marketing Approval Date: | 12/15/2008 | |
| Approved Labeled Indication: | To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma | |
| Exclusivity End Date: | 12/15/2015 | |
| Exclusivity Protected Indication* : | ||
-
